By Geoffrey Smith Investing.com — The U.S. sandwiches in jobless claims numbers between the two big monthly assessments of the labor market. Stock markets are set to open mixed as U.S. lawmakers continue to haggle over the next fiscal support measures. Germany’s factories are set to start humming again but European earnings disappoint, and gold...Read More
As expected, the BoE kept monetary policy on hold with interest rates at the historically low levels of 0.1%. This meant that the quarterly inflation report and the tone of the central bank would drive movement in GBP. Quarterly inflation report The central bank presented an improved outlook in the quarterly inflation report for this year. GDP...Read More
By Andy Bruce and David Milliken LONDON (Reuters) – The Bank of England said on Thursday it expected Britain’s economy to take longer to get back to its pre-Covid pandemic size and it warned of possible risks from taking interest rates below zero. The BoE, announcing unanimous votes by its policymakers to make no changes...Read More
(Bloomberg) — Gold and U.S. stocks could part ways during a fresh round of market turbulence, ending a three-month period in which their returns were almost yoked. Renewed deterioration of the global economy and more lockdowns to prevent Covid-19 from spreading should hit equities but leave gold standing, according to Societe Generale (OTC:SCGLY). “While the...Read More
By Tom Westbrook and Chris Prentice SINGAPORE/WASHINGTON (Reuters) – The dollar languished and just about everything else rose on Thursday, as markets took patchy U.S. economic data as a harbinger of ever more stimulus and brinkmanship on Capitol Hill as a sign that a deal on a new U.S. stimulus package is close. Following Wall...Read More
(Reuters) – The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline’s (L:GSK) experimental treatment for a common form of blood cancer. GSK’s belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement. Multiple...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.